IGMIN: We're glad you're here. Please click 'create a new query' if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click 'take me to my Query.'
Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.
At IgMin Research, we bridge the frontiers of Biology, Medicine, and Engineering to foster interdisciplinary innovation. Our expanded scope now embraces a wide spectrum of scientific disciplines, empowering global researchers to explore, contribute, and collaborate through open access.
Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.
IgMin Publications Inc., Suite 102, West Hartford, CT - 06110, USA
We aim to foster scientific connections that strengthen interdisciplinary knowledge.
Biography
Dr. Jerome H. Check is a Professor of Obstetrics & Gynecology and Head of the Division of Reproductive Endocrinology & Infertility at Cooper Medical School of Rowan University in Camden, New Jersey. He also directs the Cooper Institute for Reproductive Hormonal Disorders in Mt. Laurel, NJ, where he has led patient-care and research initiatives for over four decades.
Dr. Check earned his MD and PhD from Hahnemann University School of Medicine. He completed internship and residency at Lankenau Hospital before pursuing fellowship training in reproductive endocrinology at Jefferson Medical College. He holds board certification in Internal Medicine as well as Endocrinology, Diabetes & Metabolism, and is a Fellow of the American College of Obstetricians and Gynecologists (FACOG).
His clinical focus encompasses in‑vitro fertilization (IVF), donor egg programs, and hormonal treatments, aiming to optimize pregnancy outcomes with minimal intervention. Dr. Check has authored or co-authored over 800 publications and presentations. Notably, he has investigated progesterone-induced blocking factor (PIBF) in pregnancy and cancer, exploring mifepristone’s therapeutic potential in oncology.
His 2019 review in Anticancer Research, conducted with Diane Check, examined the role of PIBF suppression in cancer palliation and survival. Beyond academic research, Dr. Check is recognized in the community as a top physician—earning accolades like “Best Doctors of South Jersey” and “Top Docs for Women”.
With an illustrious career spanning patient care, education, and translational research, Dr. Check remains at the forefront of reproductive endocrinology and hormonal disorder therapies.
Research Interest
Dr. Jerome H. Check’s research spans reproductive endocrinology, infertility treatment, hormonal regulation, and translational cancer therapies. His clinical investigations focus on optimizing in-vitro fertilization (IVF), ovulation induction, and luteal phase support using cost-effective, minimally invasive protocols. He is a leading researcher in understanding the role of progesterone-induced blocking factor (PIBF) in maintaining pregnancy and its immunomodulatory potential in oncology. Dr. Check has also explored the therapeutic use of mifepristone in managing cancers such as lung, pancreatic, breast, and glioblastoma, hypothesizing its benefits through PIBF suppression. His studies integrate endocrinology and immunology to develop non-toxic treatment alternatives for hormone-sensitive conditions. With over 800 published works, he remains committed to bridging patient care and laboratory research, targeting both infertility outcomes and novel cancer therapies. His ongoing work continues to shape protocols in assisted reproduction, hormonal disorders, and experimental oncology, offering hope for cost-effective and innovative clinical solutions.
Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.
byJerome H Check, Brooke Neumann, Diane L Check and Michael Sobel
Most studies find lower live-delivered pregnancy rates (LDPRs) following in vitro fertilization-embryo transfer (IVF-ET) in women with diminished oocyte reserve (DOR) vs. normal oocyte reserve (NOR) even in a younger population. How much of a discrepancy may depend on the degree of oocyte depletion in the DOR group and the follicular stimulation protocol. Some fertility specialists favor an FSH receptor up-regulation technique as the protocol to attain the maximum LDPRs in women with DOR. The objective of this study was to compare chemical, cli...nical, and LDPRs following IVF-ET to determine if the main time of embryo loss is very early, as evidenced by the largest discrepancy occurring in attaining even a chemical pregnancy, and/ or a large discrepancy between a chemical pregnancy and attaining a clinical pregnancy (ultrasound evidence of a gestational sac) or later losses as evidenced by showing a greater loss rate from clinical evidence of pregnancy to live delivery in those with DOR compared to NOR. Overall, the DOR group, with a mean serum anti-Mullerian hormone (AMH) level of 0.42 ng/mL, had 50% as much chance to have an LDPR/transfer as women with NOR (AMH of 4.66) despite the same number of day 3 embryos transferred. The main reduction in LDPRs occurred from embryo transfer failing to attain a positive clinical pregnancy in the DOR group. The least discrepancy was from attaining a clinical pregnancy to live delivery. Thus, for NOR from positive pregnancy test 59% of this younger age group will have a live delivery vs. 50% for DOR. Thus, the reduction in LDPRS/transfer in young women with DOR vs. NOR seems mostly very early so the DOR group does not even attain a positive serum beta human chorionic gonadotropin level. This suggests that this inferiority in attaining a live delivery may be related to aneuploidy involving large chromosomes or a marked decrease in the mitochondrial DNA of the embryo.
0000-0002-2351-4595 
